ArticleBreast cancer research : BCR2010
Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort.
Article in Breast cancer research : BCR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 104 citations in OpenAlex.
- Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.BMC cancer · 2022Article
- Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study.International journal of women's health · 2021Article
- Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.Breast (Edinburgh, Scotland) · 2020Article
- Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma.Archives of gynecology and obstetrics · 2020Article
- Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.BMC cancer · 2018Article
- Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer.Oncotarget · 2017Article
- Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.Breast cancer research : BCR · 2017Article
- Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort.Breast cancer research : BCR · 2016Article
- Adjuvant chemotherapy in elderly patients with primary breast cancer: are women ≥65 undertreated?Journal of cancer research and clinical oncology · 2016Article
- Dietary patterns and endometrial cancer risk in the California Teachers Study cohort.Cancer causes & control : CCC · 2015Article
- Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study.Breast cancer research : BCR · 2014Article
- Dietary patterns and breast cancer risk in the California Teachers Study cohort.The American journal of clinical nutrition · 2013Article
- Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS.American journal of epidemiology · 2013Article
- Anthropometric, behavioral, and female reproductive factors and risk of multiple myeloma: a pooled analysis.Cancer causes & control : CCC · 2013Article
- Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Alcohol consumption and breast cancer risk among postmenopausal women following the cessation of hormone therapy use: the California Teachers Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012Article
- Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort.Cancer causes & control : CCC · 2012Article
- The effect of physiological concentrations of sex hormones, insulin, and glucagon on growth of breast and prostate cells supplemented with unmodified human serum.In vitro cellular & developmental biology. Animal · 2010Article
- Viruses and breast cancer.Cancers · 2010Article
- Breast cancer incidence and overdiagnosis in Catalonia (Spain).Breast cancer research : BCR · 2010Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
Abstract
introductionRecent, international declines in breast cancer incidence are unprecedented, and the causes remain controversial. Few data sources can address breast cancer incidence trends according to pertinent characteristics like hormone therapy use history.
methodsWe used the prospective California Teachers Study to evaluate changes in self-reported use of menopausal hormone therapy (HT) between 1995 to 1996 and 2005 to 2006 and age-adjusted breast cancer incidence among 74,647 participants aged 50 years or older. Breast cancer occurrence was determined by linkage with the California Cancer Registry.
resultsDuring 517,286 woman years of follow up, 565 in situ and 2,668 invasive breast cancers were diagnosed. In situ breast cancer incidence rates in this population did not change significantly from 2000 to 2002 to 2003 to 2005, whereas rates of invasive breast cancer declined significantly by 26.0% from 528.0 (95% confidence intervals (CI) = 491.1, 564.9) per 100,000 women in 2000 to 2002 to 390.6 (95% CI = 355.6, 425.7) in 2003 to 2005. The decline in invasive breast cancer incidence rates was restricted to estrogen receptor-positive tumors. In 1996 to 1999 and 2000 to 2002 invasive breast cancer incidence was higher for women who reported current HT use especially estrogen-progestin (EP) use at baseline than for never or past users; but by 2003 to 2005 rates were comparable between these groups. For women who were taking EP in 2001 to 2002,75% of whom had stopped use by 2005 to 2006, incidence had declined 30.6% by 2003 to 2005 (P = 0.001); whereas incidence did not change significantly for those who never took HT (P = 0.33).
conclusionsFew data resources can examine prospectively individual HT use and breast cancer diagnosis. Stable in situ breast cancer rates imply consistent levels of screening and suggest recent declines in invasive breast cancer to be explained predominantly by changes in HT use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.